Drugs / Salcaprozate Sodium
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05794243 Background | Mar → Jun 2023 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT04682106 Background | May → Nov 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salcaprozate Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794243 ↗ |
| Known as | SNAC | “8 Milligrams (mg) LY3493269 + 600 mg Salcaprozate Sodium (SNAC)” NCT04682106 ↗1“Drug: Salcaprozate Sodium (SNAC)” NCT05794243 ↗ |
| Route | Oral | “Administered orally.” NCT04682106 ↗ |